Cost vs Efficacy · 5 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
THP (Docetaxel) Variant #01 | ERBB2 | R 78 650 | 21d | ~16.5 mo | ~36.2 mo | ~24 | ~R 1 887 607 PFS proxy · indirect | 8 |
TCHP (Docetaxel) Variant #01 | ERBB2 | R 77 812 | 21d | — | — | — | — | 1 |
TCHP (Paclitaxel) Variant #01 | ERBB2 | R 76 852 | 21d | — | — | — | — | — |
TCHP (Docetaxel, SC Trastuzumab) Variant #01 Partial | ERBB2 | R 67 374 | 21d | — | — | — | — | — |
Lapatinib and Paclitaxel (TL) Variant #01 | ERBB2 | R 39 897 | 28d | — | ~27.8 mo | — | — | 1 |
Lapatinib and Trastuzumab Variant #02 | ERBB2 | R 38 538 | 28d | ~2.6 mo | ~14.0 mo | ~3 | ~R 115 613 PFS proxy · indirect | 2 |
THL (Paclitaxel) Variant #02 | ERBB2 | R 34 478 | 28d | — | — | — | — | — |
TCyH (Docetaxel) Variant #01 | ERBB2 | R 17 123 | 21d | — | — | — | — | — |
Paclitaxel and Trastuzumab (TH) Variant #01 | ERBB2 | R 16 575 | 21d | ~12.9 mo | ~24.0 mo | ~19 | ~R 314 933 PFS proxy · indirect | 10 |
Docetaxel and Trastuzumab (TH) and Pyrotinib Variant #01 Partial | ERBB2 | R 13 197 | 21d | ~24.3 mo | — | ~36 | ~R 475 082 PFS proxy · indirect | 1 |
Docetaxel and Trastuzumab (TH) Variant #01 | ERBB2 | R 12 507 | 21d | ~12.4 mo | ~26.5 mo | ~18 | ~R 225 125 PFS proxy · indirect | 11 |
Trastuzumab monotherapy Variant #04 | ERBB2 | R 10 438 | 21d | — | — | — | — | 2 |
CVAP Variant #01 | — | R 6 595 | 21d | — | — | — | — | — |
CVAP (Prednisolone) Variant #01 | — | R 936 | 21d | — | — | — | — | — |
No neoadjuvant therapy Partial | — | — | — | ~26.4 mo | ~37.0 mo | — | — | 12 |
No neoadjuvant therapy Partial | ER | — | — | ~26.4 mo | ~37.0 mo | — | — | 12 |
16 of 16 regimens shown